Sarepta Therapeutics has appointed Michael Severino as chief executive officer, effective 28 July 2026. Severino, who will also join the board of directors, brings over 25 years of biopharmaceutical experience to the Cambridge-based precision genetic medicine company. Severino previously served as CEO of Tessera Therapeutics and held senior positions at AbbVie, where he was vice chairman and president responsible for research and development. At AbbVie, he oversaw pipeline expansion and contributed to more than a dozen approved therapies. He succeeds Doug Ingram, who is retiring after leading Sarepta through significant growth, including approvals of two exon-skipping treatments and the first one-time gene therapy for Duchenne muscular dystrophy. Ingram will serve in an advisory capacity until the end of 2026.

Sarepta Therapeutics announced the FDA has accepted supplemental New Drug Applications to convert accelerated approvals for Duchenne muscular dystrophy therapies AMONDYS 45 and VYONDYS 53 to traditional approvals. The PDUFA action date is set for 28 February 2027. The applications are supported by the ESSENCE confirmatory study and real-world evidence from over 1,800 treated patients. This could strengthen the regulatory foundation of Sarepta's exon-skipping franchise. The development may help diversify Sarepta's regulatory position in DMD treatment, potentially offsetting concentration risk around its ELEVIDYS therapy. ELEVIDYS recently received an FDA boxed warning for acute liver injury in November 2025. Sarepta's narrative projects $1.4 billion revenue and $87.3 million earnings by 2029, requiring a 13.3% yearly revenue decline from current levels.

Sarepta Therapeutics reported statutory profits that disappointed investors, with underlying concerns emerging from the earnings analysis. The company increased its share count by 7.4% over the past year, diluting per-share returns despite generating net income. The biotechnology firm was unprofitable three years ago and last year, making year-on-year growth comparisons difficult. Whilst the company achieved profit over the last 12 months, earnings per share would have been stronger without the share dilution. Additionally, Sarepta's profit received a significant boost from unusual items worth $52 million in the last 12 months. These one-off contributions may make statutory profit a poor indicator of underlying earnings power. The combination of share dilution and unusual items raises questions about the sustainability of the company's reported profitability.